Research work · 2017

Guideline for the investigation and management of eosinophilia

Nauman M. Butt, Jonathan Lambert, Sahra Ali, Philip A. Beer, Nicholas C.P. Cross, Andrew S. Duncombe, Joanne C Ewing, Claire N. Harrison, Steven Knapper, Donal P. McLornan, Adam J. Mead, Deepti H. Radia, Barbara Jane Bain

British Journal of Haematology

Abstract

Key recommendations• The underlying cause of eosinophilia should be sought and possible eosinophil-associated end-organ damage should be evaluated (Grade 1B).Assessment of underlying cause • A detailed medical history should be taken and a thorough physical examination should be performed (Grade 1C).The history should include: o assessment for allergic disorders, skin rashes and cardiorespiratory, gastrointestinal and constitutional symptoms.o a detailed travel history, particularly for tropical travel; travel even in the remote past may be relevant.o a detailed drug history.• All patients should have a full blood count, blood film examination and routine tests of renal and liver function, a bone profile, lactate dehydrogenase, erythrocyte sedimentation rate and/or C-reactive protein and vitamin B12 assay (Grade 1C) • Patients who are otherwise well with mild to moderate eosinophilia between 0Á5 and 1Á5 3 10 9 /l may not require further testing.Patients with systemic symptoms and those with persistent eosinophilia (at least 1Á5 3 10 9 /l), irrespective of suspected organ damage, should be considered for additional testing for an underlying cause • Specific causes of reactive eosinophilia, based on clinical suspicion, should be confirmed or excluded at an early stage by appropriate testing (Grade 1C).• Patients with an eosinophil count of at least 1Á5 3 10 9 /l with no obvious cause should be investigated for a possible haematological neoplasm with clonal eosinophilia,

Download PDF

DOI: 10.1111/bjh.14488